University of Leicester
Browse

Strengthening screening for infectious diseases and vaccination among migrants in Europe: What is needed to close the implementation gaps?

Download (286.66 kB)
Version 2 2020-05-27, 15:28
Version 1 2020-05-27, 15:27
journal contribution
posted on 2020-05-27, 15:28 authored by Teymur Noori, Sally Hargreaves, Christina Greenaway, Marieke van der Werf, Matt Driedger, Rachael L Morton, Charles Hui, Ana Requena-Mendez, Eric Agbata, Daniel T Myran, Manish Pareek, Ines Campos-Matos, Rikke Thoft Nielsen, Jan Semenza, Laura B Nellums, Kevin Pottie, ECDC ad hoc scientific panel
Migration to the European Union (EU)/European Economic Area (EEA) affects the epidemiology of infectious diseases, including tuberculosis (TB), HIV, hepatitis B/C, and parasitic diseases. Some sub-populations of migrants are also considered to be an under-immunised group and thus at risk of vaccine-preventable diseases. Providing high-risk migrants with timely and efficacious screening and vaccination, and understanding how best to implement more integrated screening and vaccination programmes into European health systems ensuring linkage to care and treatment, is key to improving the health of migrants and their communities, alongside meeting national and regional targets for infection surveillance, control, and elimination. The European Centre for Disease Prevention and Control (ECDC) has responded to calls to action to improve migrant health and strengthen universal health coverage by developing evidence-based guidance for policy makers, public health experts, and front-line healthcare professionals on how to approach screening and vaccination in newly arrived migrants within the EU/EEA. In this Commentary, we provide a perspective towards developing efficacious screening and vaccination of newly arrived migrants, with a focus on defining implementation challenges and evidence gaps in high-migrant receiving EU/EEA countries. There is a need now to leverage the increasing momentum around migrant health to both strengthen the evidence-base and to advocate for universal access to health care for all migrants in the EU/EEA, including undocumented migrants. This should include voluntary, confidential, and non-stigmatising screening and vaccination that should be free of charge and facilitate linkage to appropriate care and treatment.

Funding

SH is funded by the National Institute for Health Research (NIHR Advanced Fellowship NIHR300072), the Academy of Medical Sciences (SBF005\1111), and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) through an ESCMID Study Group for Infections in Travellers and Migrants (ESGITM) research grant. MP is supported by the National Institute for Health Research (NIHR Post-Doctoral Fellowship, PDF-2015-08-102). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the UK Department of Health.

History

Citation

Travel Medicine and Infectious Disease Available online 7 May 2020, 101715

Version

  • AM (Accepted Manuscript)

Published in

Travel Medicine and Infectious Disease

Pagination

101715

Publisher

Elsevier BV

issn

1477-8939

eissn

1873-0442

Copyright date

2020

Available date

2020-04-26

Spatial coverage

EU / EEA

Language

eng

Publisher version

https://www.sciencedirect.com/science/article/pii/S1477893920301836

Usage metrics

    University of Leicester Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC